Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Consensus Recommendation of “Buy” from Brokerages

Kymera Therapeutics, Inc. (NASDAQ:KYMR) has received a consensus recommendation of “Buy” from the twenty-two research firms that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, nineteen have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $116.30.

KYMR has been the subject of a number of research reports. Stephens increased their target price on shares of Kymera Therapeutics from $65.00 to $110.00 and gave the company an “overweight” rating in a research report on Thursday, December 11th. BTIG Research set a $138.00 price objective on Kymera Therapeutics in a research note on Monday, December 8th. Truist Financial increased their price objective on Kymera Therapeutics from $80.00 to $116.00 and gave the company a “buy” rating in a report on Tuesday, December 9th. Wells Fargo & Company raised their target price on Kymera Therapeutics from $69.00 to $116.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 9th. Finally, Wall Street Zen raised Kymera Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th.

Kymera Therapeutics Price Performance

Shares of Kymera Therapeutics stock opened at $75.21 on Thursday. The firm has a market cap of $5.41 billion, a PE ratio of -20.95 and a beta of 2.21. Kymera Therapeutics has a 1 year low of $19.44 and a 1 year high of $103.00. The stock has a fifty day moving average price of $73.78 and a 200-day moving average price of $57.60.

Kymera Therapeutics (NASDAQ:KYMR) last posted its quarterly earnings results on Tuesday, November 4th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.71) by ($0.19). Kymera Therapeutics had a negative net margin of 674.81% and a negative return on equity of 32.92%. The company had revenue of $2.76 million for the quarter, compared to the consensus estimate of $23.15 million. As a group, equities analysts anticipate that Kymera Therapeutics will post -2.79 EPS for the current fiscal year.

Insider Buying and Selling at Kymera Therapeutics

In related news, CEO Nello Mainolfi sold 30,000 shares of the firm’s stock in a transaction that occurred on Wednesday, December 31st. The shares were sold at an average price of $78.06, for a total value of $2,341,800.00. Following the completion of the transaction, the chief executive officer directly owned 663,077 shares of the company’s stock, valued at approximately $51,759,790.62. This trade represents a 4.33% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Jared Gollob sold 49,307 shares of Kymera Therapeutics stock in a transaction that occurred on Monday, December 8th. The shares were sold at an average price of $88.67, for a total transaction of $4,372,051.69. Following the completion of the transaction, the insider owned 109,992 shares of the company’s stock, valued at $9,752,990.64. This represents a 30.95% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 450,895 shares of company stock valued at $39,608,051. Insiders own 16.01% of the company’s stock.

Hedge Funds Weigh In On Kymera Therapeutics

A number of large investors have recently made changes to their positions in the stock. BVF Inc. IL lifted its holdings in Kymera Therapeutics by 6.6% during the 2nd quarter. BVF Inc. IL now owns 5,502,710 shares of the company’s stock worth $240,138,000 after purchasing an additional 340,909 shares in the last quarter. Siren L.L.C. increased its position in shares of Kymera Therapeutics by 9.1% during the first quarter. Siren L.L.C. now owns 3,240,313 shares of the company’s stock valued at $88,687,000 after buying an additional 270,580 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Kymera Therapeutics by 5.2% in the second quarter. Geode Capital Management LLC now owns 1,193,112 shares of the company’s stock worth $52,075,000 after buying an additional 59,347 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of Kymera Therapeutics by 121.5% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 896,404 shares of the company’s stock valued at $24,535,000 after acquiring an additional 491,737 shares during the period. Finally, Holocene Advisors LP bought a new position in shares of Kymera Therapeutics in the third quarter valued at approximately $47,563,000.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.